Correction to press release: “NeuroVive resolves on a Rights issue of MSEK 123.8 for continued drug development, and new publication date of the 2018 Year End Report”
Lund, Sweden, 11 December 2018 – NeuroVive Pharmaceutical AB(publ)("NeuroVive" or "the Company") announces adjustment of the following dates in the press release, published on December 10, 2018:· Last day of trading in shares including the right to participate in the Rights Issuewith preferential right; · First day for trading in shares without the right to participate in the Rights issuewith preferential rights; and · Record date for the receipt of subscription rights and right to participate inthe Rights issue with preferential rights. Below are the adjusted dates: